Intervention not reported
Mortality · Adults (>18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)
The intervention showed no clear difference in mortality (low certainty).
1 finding from 1 review
Intervention not reported
Improvement in WHO Functional Class · Adults (>18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)
The intervention showed no clear difference in improvement in WHO Functional Class (low certainty).
1 finding from 1 review
Intervention not reported
Serious Adverse Events (Participants with one or more event) · Adults (>18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)
It is very uncertain whether the intervention changes serious Adverse Events (Participants with one or more event) (very low certainty).
1 finding from 1 review
Overall mortality · preterm infants with severe pulmonary dysfunction
Rescue high‐frequency jet ventilation showed no clear difference in overall mortality compared with conventional ventilation (low certainty).
1 finding from 1 review
Mortality before cross‐over · preterm infants with severe pulmonary dysfunction
Rescue high‐frequency jet ventilation probably leads to lower mortality before cross‐over compared with conventional ventilation (moderate certainty).
1 finding from 1 review
Chronic lung disease · preterm infants with severe pulmonary dysfunction
Rescue high‐frequency jet ventilation showed no clear difference in chronic lung disease at 28 days of birth (CLD 28 days) compared with conventional ventilation (low certainty).
2 findings from 1 review
Severe intraventricular haemorrhage · preterm infants with severe pulmonary dysfunction
Rescue high‐frequency jet ventilation showed no clear difference in severe intraventricular haemorrhage (grades 3 and 4) compared with conventional ventilation (low certainty).
1 finding from 1 review
Neurodevelopmental outcomes · preterm infants with severe pulmonary dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dyspnoea ‐ CRQ dyspnoea Scale 1 to 7. Higher is better and 0.5 units is a clinically important difference · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change in SGRQ total score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change in incremental shuttle walk distance · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change from baseline in 6MWT (metres) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Exercise capacity · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change in quality of life · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Hospital admission (exacerbation) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (exacerbation) compared with long‐acting beta2‐agonist alone (low certainty).
1 finding from 1 review
Mortality (all cause) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in mortality (all cause) compared with long‐acting beta2‐agonist alone (low certainty).
1 finding from 1 review
Change in baseline trough FEV1 · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life SGRQ responder analysis at 6 months · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium probably leads to higher quality of life SGRQ responder analysis at 6 months compared with tiotropium alone (moderate certainty).
1 finding from 1 review
Hospital admissions · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (all cause) compared with tiotropium alone (moderate certainty).
1 finding from 1 review
Hospital admission (exacerbation) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (exacerbation) compared with tiotropium alone (low certainty).
1 finding from 1 review